Community knowledge and practices regarding antibiotic use in rural Mozambique: where is the starting point for prevention of antibiotic resistance?


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
29 Jul 2020
Historique:
received: 06 02 2020
accepted: 12 07 2020
entrez: 31 7 2020
pubmed: 31 7 2020
medline: 28 8 2020
Statut: epublish

Résumé

Antibiotic misuse and other types of unnecessary use of antibiotics can contribute to accelerate the process of antibiotic resistance, which is considered a global concern, mostly affecting low-and middle-income countries (LMICs). In Mozambique there is limited evidence on community knowledge and practices regarding antibiotics and antibiotic resistance. As part of the ABACUS project, this paper describes knowledge and practices of antibiotic use among the general population in the semi-rural district of Manhiça to inform evidence-based communication intervention strategies for safer antibiotic use. The study was conducted in Manhiça, a semi-rural district of Southern Mozambique. Sixteen in-depth interviews and four focus group discussions (FGDs) were conducted with community members to explore lay knowledge and practices regarding antibiotics and awareness of antibiotic resistance. The qualitative data was analysed using a combination of content and thematic analysis. The SRQR guidelines for reporting qualitative studies was performed. Although participants did not hold any consistent knowledge of antibiotics, their visual recognition of amoxicillin (distinct red yellow capsule) was acceptable, but less so for different types and brands of antibiotics. The majority of participants were aware of the term 'antibiotic', yet the definition they gave was rarely backed by biomedical knowledge. Participants associated antibiotics with certain colours, shapes and health conditions. Participants reported common habits that may contribute to resistance: not buying the full course, self-medication, sharing medicines and interruption of treatment. Most had never heard of the term 'antibiotic resistance' but were familiar with the phenomenon. They often understood the term 'resistance' as treatment failure and likened 'resistance' to non-compliance, ineffective medication, disease resistance or to an inability of the physical body to respond to it. There is a broad understanding of the importance of medication compliance but not specifically of antibiotic resistance. In addition, there is a recognized gap between knowledge of responsible drug compliance and actual behaviour. Future qualitative research is required to further explore what determines this behaviour. The existing ability to visually identify amoxicillin by its distinct red and yellow appearance is informative for future awareness and behavioural change campaigns that may incorporate visual aids of antibiotics.

Sections du résumé

BACKGROUND BACKGROUND
Antibiotic misuse and other types of unnecessary use of antibiotics can contribute to accelerate the process of antibiotic resistance, which is considered a global concern, mostly affecting low-and middle-income countries (LMICs). In Mozambique there is limited evidence on community knowledge and practices regarding antibiotics and antibiotic resistance. As part of the ABACUS project, this paper describes knowledge and practices of antibiotic use among the general population in the semi-rural district of Manhiça to inform evidence-based communication intervention strategies for safer antibiotic use.
METHODS METHODS
The study was conducted in Manhiça, a semi-rural district of Southern Mozambique. Sixteen in-depth interviews and four focus group discussions (FGDs) were conducted with community members to explore lay knowledge and practices regarding antibiotics and awareness of antibiotic resistance. The qualitative data was analysed using a combination of content and thematic analysis. The SRQR guidelines for reporting qualitative studies was performed.
RESULTS RESULTS
Although participants did not hold any consistent knowledge of antibiotics, their visual recognition of amoxicillin (distinct red yellow capsule) was acceptable, but less so for different types and brands of antibiotics. The majority of participants were aware of the term 'antibiotic', yet the definition they gave was rarely backed by biomedical knowledge. Participants associated antibiotics with certain colours, shapes and health conditions. Participants reported common habits that may contribute to resistance: not buying the full course, self-medication, sharing medicines and interruption of treatment. Most had never heard of the term 'antibiotic resistance' but were familiar with the phenomenon. They often understood the term 'resistance' as treatment failure and likened 'resistance' to non-compliance, ineffective medication, disease resistance or to an inability of the physical body to respond to it.
CONCLUSION CONCLUSIONS
There is a broad understanding of the importance of medication compliance but not specifically of antibiotic resistance. In addition, there is a recognized gap between knowledge of responsible drug compliance and actual behaviour. Future qualitative research is required to further explore what determines this behaviour. The existing ability to visually identify amoxicillin by its distinct red and yellow appearance is informative for future awareness and behavioural change campaigns that may incorporate visual aids of antibiotics.

Identifiants

pubmed: 32727445
doi: 10.1186/s12889-020-09243-x
pii: 10.1186/s12889-020-09243-x
pmc: PMC7389384
doi:

Substances chimiques

Anti-Bacterial Agents 0
Amoxicillin 804826J2HU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1183

Subventions

Organisme : INDEPTH Network
ID : IND/002/2016

Références

Infect Drug Resist. 2009;2:1-11
pubmed: 21694883
Int J Infect Dis. 2017 Jul;60:83-87
pubmed: 28546075
J Gen Intern Med. 2012 Jul;27(7):766-72
pubmed: 22065334
BMC Public Health. 2011 Jul 07;11:538
pubmed: 21736711
J Clin Diagn Res. 2015 Nov;9(11):SC21-4
pubmed: 26674397
Antimicrob Resist Infect Control. 2015 Jan 28;4:1
pubmed: 25717374
BMC Infect Dis. 2010 Sep 16;10:270
pubmed: 20846407
PLoS One. 2014 Mar 21;9(3):e92323
pubmed: 24658124
Int J Environ Res Public Health. 2012 Oct 05;9(10):3519-29
pubmed: 23202760
PLoS One. 2015 Sep 17;10(9):e0138179
pubmed: 26379031
J Antimicrob Chemother. 2007 Aug;60 Suppl 1:i63-8
pubmed: 17656386
Antimicrob Resist Infect Control. 2012 Nov 23;1(1):38
pubmed: 23176763
Int J Environ Res Public Health. 2018 Dec 23;16(1):
pubmed: 30583571
PLoS One. 2015 Feb 12;10(2):e0117910
pubmed: 25675405
BMC Clin Pharmacol. 2011 Nov 15;11:18
pubmed: 22085536
J Antimicrob Chemother. 2007 Apr;59(4):727-38
pubmed: 17307770
Am J Infect Control. 2006 Oct;34(8):495-502
pubmed: 17015154
J Pharm Policy Pract. 2017 Apr 4;10:13
pubmed: 28392925
J Infect Dev Ctries. 2011 May 28;5(5):338-47
pubmed: 21628809
J Infect Dev Ctries. 2014 Apr 15;8(4):424-9
pubmed: 24727507
J Infect Public Health. 2018 Jan - Feb;11(1):30-34
pubmed: 28285971
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
SAHARA J. 2007 Nov;4(3):695-706
pubmed: 18185896
BMC Med Educ. 2013 Dec 09;13:163
pubmed: 24321449
BMC Pharmacol Toxicol. 2015 Apr 27;16:11
pubmed: 25928897
Braz J Infect Dis. 2005 Aug;9(4):288-91
pubmed: 16270120
PLoS One. 2013 Dec 23;8(12):e84177
pubmed: 24376793
PLoS One. 2019 Aug 22;14(8):e0221452
pubmed: 31437215
Res Social Adm Pharm. 2014 Jan-Feb;10(1):168-84
pubmed: 23665078
Health Expect. 2014 Oct;17(5):651-63
pubmed: 22583645
BMC Pharmacol Toxicol. 2014 May 19;15:26
pubmed: 24887310
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
BMJ. 1998 Sep 5;317(7159):637-42
pubmed: 9727992
South Afr J HIV Med. 2016 Jun 09;17(1):418
pubmed: 29568602
Int J Epidemiol. 2013 Oct;42(5):1309-18
pubmed: 24159076
Cad Saude Publica. 2007 Dec;23(12):2845-52
pubmed: 18157326
Prev Med. 2002 Mar;34(3):346-52
pubmed: 11902851
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
Public Health. 2019 Mar;168:92-101
pubmed: 30716570
Antimicrob Resist Infect Control. 2019 Oct 21;8:161
pubmed: 31649818
Nat Med. 1998 May;4(5):545-6
pubmed: 9585218
Saudi Med J. 2015 Mar;36(3):328-34
pubmed: 25737176
Wellcome Open Res. 2017 Jul 28;2:58
pubmed: 29707652

Auteurs

Olga Cambaco (O)

Centro de Investigação em Saúde de Manhiça (CISM), Manhiça, Mozambique.

Yara Alonso Menendez (Y)

Centro de Investigação em Saúde de Manhiça (CISM), Manhiça, Mozambique.

John Kinsman (J)

Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.

Betuel Sigaúque (B)

Centro de Investigação em Saúde de Manhiça (CISM), Manhiça, Mozambique.

Heiman Wertheim (H)

Department of Medical Microbiology and Center for Infectious Diseases, Radboudumc, Nijmegen, Netherlands.

Nga Do (N)

Oxford University Clinical Research Unit, Hanoi, Vietnam.

Margaret Gyapong (M)

Centre for Health Policy and Implementation Research, Kintampo, Ghana.

Johannes John-Langba (J)

University of Kwazulu-Natal, Durban, South Africa.

Esperança Sevene (E)

Centro de Investigação em Saúde de Manhiça (CISM), Manhiça, Mozambique.
Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique.

Khátia Munguambe (K)

Centro de Investigação em Saúde de Manhiça (CISM), Manhiça, Mozambique. khatia.munguambe@manhica.net.
Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique. khatia.munguambe@manhica.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH